Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Penelope MacRae

Advertisement
Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Accusations Fly In Messy Ranbaxy Compensation Battle

The ongoing fight by Daiichi Sankyo for compensation from India’s Singh brothers over the company’s disastrous purchase of generic drugs giant Ranbaxy has heated up, with the Japanese firm now accusing the tycoons of not telling the truth about the value of assets meant to serve as security for damages.

India Legal Issues

India’s New National Health Care Policy Recycles Old Targets

India’s Health Minister says a new national health care roadmap marks a “huge milestone” towards fixing the country’s failing medical delivery system. But critics say while the scheme is a step in the right direction, it largely recycles old, unmet goals from years ago and caution that implementation will be key.

India Policy

Glenmark Wins ‘Milestone’ US Nod For COPD Trial In Innovation Push

India’s Glenmark sees the US FDA clearance of its Phase II plan for a novel formulation for COPD as a milestone in its quest to transform into a more innovation-led company and position itself for future growth.

India Research & Development

India's Stent Price Slash Creating Climate Of Fear, Foreign Device-Makers Say

An association representing international research-based medtech companies says the Indian government’s imposition of stiff price controls on cardiac stents has sown an “atmosphere of fear” in the industry, and it warns that the move could stifle patient access to innovative treatments.

India Pricing Strategies

Daiichi Seeks To Stall Singh Asset Sales In Ranbaxy Compensation Battle

Daiichi Sankyo has chalked up a procedural win in its ongoing court battle for compensation from Indian tycoons Malvinder and Shivinder Singh over the Japanese company’s ill-fated acquisition of Indian generic giant Ranbaxy.

Commercial Legal Issues

Indian Teen’s Fight For Lifesaving TB Drug Highlights Access Issues

An Indian teenager’s court battle for a new tuberculosis drug that doctors say could save her life has cast a harsh spotlight on the slow rollout of breakthrough medicines to treat the disease in the country, one of the world’s biggest TB hotspots.

India Policy
See All
Advertisement
UsernamePublicRestriction

Register